Iomai Vaccine For Travelers' Diarrhea Blunts Severity Of Disease In Clinical Study
Tue, 06 Mar 2007 08:00 AM EST
... Iomai Corporation (Nasdaq: IOMI) today announced the publication of results from its double-blind challenge study of its vaccine patch for travelers' diarrhea. The clinical study found that volunteers who received the vaccine before being exposed to high levels of enterotoxigenic E. [click link for full article] ...
Related Topics
- Diarrhea
- Clinical Trials
- Vaccine
- Infectious Diseases
- Rotavirus
- Polio Vaccine & Cancer
- Polio Vaccine
- Polio Vaccine & Origin of HIV/AIDS
- Disease Outbreaks and Travelers
- Crohn's Disease
- Cardiovascular Diseases And Disorders
- Polio
- Vaccine Side Effects
- Pharmacology
- MMR Vaccine & (Asceptic) Meningitis
- Lyme Disease Vaccine
- Epidemiology & Prevention of Vaccine-Preventable Diseases
- Smallpox Vaccine
- Psychopharmacology
- Chickenpox Vaccine

Not Signed In -


